IBIO Archives - Page 2 of 7

Developments

iBio selects MUC16 as next immuno-oncology target program

iBio (NYSE American:IBIO) selected MUC16 as the target of its latest immuno-oncology program. MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and...

February 17, 2023

Developments

iBio receives U.S. patent for AI-engineered epitope discovery engine

iBio (NYSEA:IBIO) received a patent from the U.S. Patent and Trademark Office issued a patent entitled, “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a machine learning...

January 5, 2023

Developments

iBio to showcase RubrYc discovery engine at antibody conference

iBio (NYSEA:IBIO) will present two posters about its intelligence-powered RubrYc discovery engine at the Antibody Engineering and Therapeutics Conference in San Diego on Dec. 4-8. The conference features the latest...

December 5, 2022

Developments

iBio accelerates transformation to AI-powered biotech

iBio (NYSEA:IBIO) announced it is seeking to divest its contract development and manufacturing organization, iBio CDMO, in order to complete its transformation into an antibody discovery and development company...

November 3, 2022

Developments

iBio acquires RubrYc Therapeutics’ AI drug discovery platform and pipeline

iBio (NYSEA:IBIO) closed the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, marking an important step in iBio’s mission to bring more, and better, immunotherapies to the...

September 21, 2022

Developments

iBio updates development of next-gen COVID-19 vaccine candidate

iBio (NYSEA:IBIO) provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. Unlike first-generation COVID vaccines that seek to provide immunity by...

August 16, 2022

Developments

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

iBio (NYSE American:IBIO) is presenting a poster on IBIO-101, its monoclonal antibody candidate for the treatment of solid tumors, at Frontiers in Cancer Immunotherapy 2022 in New York May 9-11. Preclinical evaluation...

May 9, 2022

Developments

iBio to present poster highlighting better glycosylation for antibodies produced in plants via its FastPharming System

iBio (NYSE American:IBIO) senior product manager, Rachel Jordan, Ph.D., will present a poster at the annual Protein & Antibody Engineering Summit conference in Boston this week titled, “Plant-Made Antibodies...

May 2, 2022

Developments

iBio advancing vaccine program for multi-variant COVID-19 disease

iBio (NYSE American:IBIO) updated progress on its lead COVID-19 vaccine program, IBIO-202, including a recently received the FDA response to its pre-IND package for IBIO-202. In light of the feedback received, the...

January 26, 2022

Markets

JMP starts iBio at market outperform; PT $1.50

JMP Securities initiated coverage of iBio (NYSE American:IBIO) with a “market outperform” rating and price target of $1.50. The stock closed at 85 cents, up 19 cents, or 29%, on Nov. 29. iBio is a technology...

November 29, 2021

Tag - IBIO

iBio selects MUC16 as next immuno-oncology target program

iBio receives U.S. patent for AI-engineered epitope discovery engine

iBio to showcase RubrYc discovery engine at antibody conference

iBio accelerates transformation to AI-powered biotech

iBio acquires RubrYc Therapeutics’ AI drug discovery platform and pipeline

iBio updates development of next-gen COVID-19 vaccine candidate

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

iBio to present poster highlighting better glycosylation for antibodies produced in plants via its FastPharming System

iBio advancing vaccine program for multi-variant COVID-19 disease

JMP starts iBio at market outperform; PT $1.50

General

More